'Resistance' to low-dose aspirin therapy extremely rare

Patients who might benefit may not be getting needed therapy

2012-12-05

(Press-News.org) PHILADELPHIA — Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets – blood cells that clump together in the first stages of forming harmful clots – up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

In people who have suffered a heart attack, low-dose aspirin reduces the chances of a second event by about one fifth, making it perhaps one of the most cost-effective drugs currently prescribed. Although consumed widely by the worried well, the relative usefulness of low-dose aspirin in patients who have never had a heart attack is more controversial. According to previous primary prevention studies, low-dose aspirin reduces this group's very low risk of a first attack by about the same number of serious stomach bleeds it causes.

In a study of 400 healthy volunteers published online this week in Circulation, the journal of the American Heart Association, scientists from the Perelman School of Medicine at the University of Pennsylvania, went looking for people who are truly resistant to the benefits of aspirin, such as might result from a particular genetic makeup. They failed to find one case of aspirin resistance; rather, they found "pseudoresistance," due to the coating found on most brands of aspirin, often preferred by patients for the protection it is claimed to provide the stomach. What's more, a urine biomarker of platelet stickiness was not able to find which volunteers were even pseudoresistant.

The study was led by Tilo Grosser MD, research assistant professor of Pharmacology, Susanne Fries, MD, research assistant professor of Pharmacology, and Garret FitzGerald, MD, FRS, director of the Institute for Translational Medicine and Therapeutics.

"When we looked for aspirin resistance using the platelet test, it detected it in about one-third of our volunteers," said Grosser. "But, when we looked a second time at the incidence of aspirin resistance in the volunteers, the one-third that we measured who was now resistant was mostly different people. Nobody had a stable pattern of resistance that was specific to coated aspirin."

Presently a blood test using a specific device can be used in the doctor's office to diagnose "aspirin resistance." Alternatively, an FDA-approved urine test is available for an indirect marker of platelet stickiness. Either can be used to determine if a patient is likely to benefit from aspirin. However, neither approach was supported by the Penn study. The blood test picked up pseudoresistance, while the urine test failed even to segregate these individuals from those clearly responsive to aspirin.

To address the reason for this pseudoresistance, the researchers compared test results of coated aspirin with the same dose of regular uncoated aspirin in volunteer subgroups for coated versus immediate-release, uncoated aspirin. Resistance was absent in the group that took the uncoated aspirin.

The coating delayed absorption compared to immediate-release, uncoated aspirin. This led to a false impression of aspirin resistance in people taking coated aspirin. Platelets of such patients remained sensitive to aspirin when examined in a test tube, so they were not truly resistant to the action of aspirin.

Uncoated, immediate-release aspirin is generic and cheap - less than 1 cent per pill – but most low-dose aspirin taken in the U.S. is the more expensive, coated, branded variety. Although supposedly easier on the stomach, coating of aspirin has never been shown to reduce the likelihood of serious stomach bleeds compared to the same dose of uncoated aspirin.

"These studies question the value of coated, low-dose aspirin," notes FitzGerald. "This product adds cost to treatment, without any clear benefit. Indeed, it may lead to the false diagnosis of aspirin resistance and the failure to provide patients with an effective therapy. Our results also call into question the value of using office tests to look for such resistance."

INFORMATION:

Co-authors are John A. Lawson, Shiv C. Kapoor, and Gregory R. Grant, all from Penn. The research was supported by the National Heart Lung and Blood Institute (HL 54500), the National Center for Research Resources (UL1-RR-024134), the American Heart Association, and Bayer Health Care. The funding sources were not involved in the study design, or in the collection, analysis, and interpretation of data. Grosser has received consultancy fees from PLx Pharma. FitzGerald has received research funding from Bayer Health Care in partial support of this study.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital — the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

RI Hospital: Standardized road test results differ from older adults' natural driving

2012-12-05

PROVIDENCE, R.I. – If you're thinking that little old lady driving 35 miles per hour in the passing lane shouldn't be behind the wheel, you may be right. Studies at Rhode Island Hospital, and elsewhere, have shown that our driving abilities decline with age, and for those with cognitive issues such as dementia, it can be even worse. A standardized road test – much like the one teenagers take to receive their learner's permit and driver's license – is often used to measure an individual's performance, including those of older adults. But researchers at the Rhode Island ...

New test adds to scientists' understanding of Earth's history, resources

2012-12-05

GAINESVILLE, Fla. — A new study co-authored by a University of Florida researcher provides the first direct chronological test of sequence stratigraphy, a powerful tool for exploring Earth's natural resources. The model allows geologists to better understand how sedimentary rocks are related to one another in time and space and predict what types of rocks are located in different areas. The information may help scientists more reliably interpret various aspects of Earth's history such as long-term climate changes or extinction events, and also benefit companies searching ...

Studying marrow, URMC researchers accelerate blood stem cells

2012-12-05

University of Rochester Medical Center scientists are testing a new approach to speed a patient's recovery of blood counts during a vulnerable period after a stem-cell transplant, according to a study published in the journal Stem Cells. Laura M. Calvi, M.D., and Rebecca L. Porter, an M.D./Ph.D. student in Calvi's lab, reported that prostaglandin E2 (PGE2), a drug previously used to treat stomach ulcers, boosts blood production following an assault on the bone marrow from radiation or chemotherapy. Although their study was done in mice, Calvi believes it has significance ...

Women and men appear to benefit in different ways from AA participation

2012-12-05

A new study finds differences in the ways that participation in Alcoholics Anonymous (AA) helps men and women maintain sobriety. Two Massachusetts General Hospital (MGH) investigators found that, while many factors are helpful to all AA participants, some were stronger in men and some in women. For example, avoidance of companions who encourage drinking and social situations in which drinking is common had more powerful benefits for men, while increased confidence in the ability to avoid drinking while feeling sad, depressed or anxious appeared to be more important for ...

Research identifies a way to block memories associated with PTSD or drug addiction

2012-12-05

VIDEO: New research from Western University could lead to better treatments for Post-Traumatic Stress Disorder (PTSD) and drug addiction by effectively blocking memories. Steven Laviolette and Nicole Lauzon describe how... Click here for more information. New research from Western University could lead to better treatments for Post-Traumatic Stress Disorder (PTSD) and drug addiction by effectively blocking memories. The research performed by Nicole Lauzon, a PhD candidate ...

Morphing DNA hydrogel flows like liquid but remembers its original shape

2012-12-05

ITHACA, N.Y. – A bit reminiscent of the Terminator T-1000, a new material created by Cornell researchers is so soft that it can flow like a liquid and then, strangely, return to its original shape. Rather than liquid metal, it is a hydrogel, a mesh of organic molecules with many small empty spaces that can absorb water like a sponge. It qualifies as a "metamaterial" with properties not found in nature and may be the first organic metamaterial with mechanical meta-properties. Hydrogels have already been considered for use in drug delivery – the spaces can be filled with ...

Microchoreography: Researchers use synthetic molecule to guide cellular 'dance'

2012-12-05

Johns Hopkins researchers have used a small synthetic molecule to stimulate cells to move and change shape, bypassing the cells' usual way of sensing and responding to their environment. The experiment pioneers a new tool for studying cell movement, a phenomenon involved in everything from development to immunity to the spread of cancer. "We were able to use synthetic molecules small enough to slip inside the cell and activate a chemical reaction controlling cell movement, bypassing most of the steps that usually lead up to this reaction," says Andre Levchenko, Ph.D., ...

Advice for bag-in-box wine drinkers: Keep it cool

2012-12-05

Bag-in-box wines are more likely than their bottled counterparts to develop unpleasant flavors, aromas and colors when stored at warm temperatures, a new study has found. Published in ACS' Journal of Agricultural and Food Chemistry, it emphasizes the importance of storing these popular, economical vintages at cool temperatures. Helene Hopfer and colleagues explain that compounds in wine react with oxygen in the air to change the way wine looks, tastes and smells. These reactions speed up with increasing temperature. Many winemakers are moving away from the traditional ...

Plastics used in some medical devices break down in a previously unrecognized way

2012-12-05

Scientists have discovered a previously unrecognized way that degradation can occur in silicone-urethane plastics that are often considered for use in medical devices. Their study, published in ACS' journal Macromolecules, could have implications for device manufacturers considering use of these plastics in the design of some implantable devices, including cardiac defibrillation leads. Kimberly Chaffin, Marc Hillmyer, Frank Bates and colleagues explain that some implanted biomedical devices, such as pacemakers and defibrillators, have parts made of a plastic consisting ...

Communications training, surgical checklist can reduce costly postoperative complications

2012-12-05

Chicago (December 5, 2012): As the nation grapples with surging health care costs, researchers at the University of Connecticut Health Center, Farmington, and Saint Francis Hospital and Medical Center, Hartford, have confirmed two simple cost-effective methods to reduce expensive postoperative complications—communications team training and a surgical checklist. Investigators found that when surgical teams completed communications training and a surgical procedure checklist before, during, and after high-risk operations, patients experienced fewer adverse events such as ...

'Resistance' to low-dose aspirin therapy extremely rare

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: